Shares of CSPC PHARMA (01093) surged more than 10% in morning trading. At the time of writing, the stock was up 10.61% to HK$7.40, with a turnover of HK$662 million.

The company announced that its Phase III clinical trial for SYS6010 in combination with Enlansubai monoclonal antibody for the treatment of driver gene-negative non-small cell lung cancer (NSCLC), designated SYS6010–022 (SYNSTAR-04), has officially commenced in China. The first patient enrollment is projected for completion by July 2026. SYS6010 is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR) developed by the group. It consists of a humanized anti-EGFR monoclonal antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker.

The SYS6010–022 (SYNSTAR-04) study is a randomized, open-label, multi-center Phase III trial designed to evaluate the efficacy and safety of SYS6010 combined with Enlansubai monoclonal antibody compared to immunotherapy plus platinum-based chemotherapy in patients with driver gene-negative, PD-L1 positive locally advanced or metastatic NSCLC. The group previously received feedback from the Center for Drug Evaluation of China's National Medical Products Administration in May 2026, agreeing to proceed with this clinical trial. Patient recruitment and screening are currently being actively advanced.